WaVe生命科学 WVE 深 沪
等待开盘 10-10 09:30:00 美东时间
8.10
+0.750
+10.20%
华盛通- 最 高8.31
- 今 开7.38
- 成交量 288.00万股
- 最 低 7.325
- 昨 收 7.35
- 总市值 12.47亿
- 52周最高 16.735
- 市盈率 静 --
- 换手率 1.87%
- 52周最低 5.28
- 委 比 62.82%
- 总股本 1.54亿
- 历史最高 56.00
- 量 比 1.42
- 振 幅 13.40%
- 历史最低 1.16
- 每 手 1
- 风险率 1.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wave Life Sciences Highlights WVE-007 Obesity Treatment
The latest update is out from Wave Life Sciences ( ($WVE) ). On September 24, 2...
09-25 16:14
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
Wave Life Sciences Ltd. announces a virtual Research Day on October 29, 2025, and participation in upcoming investor conferences, including Bernstein's Healthcare Forum, Stifel's Cardiometabolic Forum, and Chardan's Genetic Medicines Conference. Details and live webcasts are available on their website. The company focuses on RNA medicines to treat various disorders and has a diversified pipeline in development.
09-18 12:30
Peering Into WAVE Life Sciences's Recent Short Interest
WAVE Life Sciences's (NYSE:WVE) short interest as a percent of float has risen ...
09-13 04:01
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Wave Life Sciences Announces Data From 200 Mg Single And Multidose And 400 Mg Single Dose Cohorts Of Ongoing Phase 1b/2a Restoraation-2 Study Evaluating WVE-006 As Treatment For AATD
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever
09-03 19:32
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences announced positive results from the Phase 1b/2a RestorAATion-2 study of WVE-006 for alpha-1 antitrypsin deficiency (AATD). Data showed significant increases in wild-type M-AAT protein, reductions in mutant Z-AAT, and supportive safety profile, enabling monthly or less frequent dosing. WVE-006 demonstrated the ability to restore physiological AAT production, including during an acute phase response. Further data from the 400 mg ...
09-03 11:30
Wave Life Sciences gains as JPMorgan suspends rating
Wave Life Sciences (NASDAQ:WVE) quickly hit highs of the day, rising 5%, after JPMorgan suspended its rating, price target, and estimates on the company. Some investors may be speculating that JPMorg...
08-16 00:43
Wave Life Sciences Shareholders Approve Key Proposals
An update from Wave Life Sciences ( ($WVE) ) is now available. On August 5, 202...
08-12 05:50
